QIBA CT Volumetry Biomarker Committee (TC) Update Call
15 December 2014 at 11 AM CT
Call Summary

In attendance:
Samuel G. Armato, III, PhD (Co-Chair)  Rudresh Jarecha, MBBS  Ehsan Samei, PhD 
Gregory V. Goldmacher, MD, PhD, (Co-Chair)  Philip F. Judy, PhD  Doug Steinfeld
Maria Athelogou, PhD  Hyun Grace Kim, PhD  Daniel Sullivan, MD
Hubert Beaumont, PhD  James Mulshine, MD  Ying Tang, PhD
Andrew Buckler, MS  Nancy Obuchowski, PhD  Luduan Zhang, PhD
Charles Fenimore, PhD  Adele Peskin, PhD  Binsheng Zhao, DSc
David Gustafson, PhD  Nicholas Petrick, PhD

RSNA:
Joe Koudelik  Julie Lisiecki

Agenda: Future planning and Field Test Discussion

Discussion:
• Steps needed to complete the Profile and achieve Field Test / Technically Confirmed Status:
  o Public Comments to be resolved
    ▪ Drs. Goldmacher and Petrick and Mr. O’Donnell are working to resolve public comments with a goal of completion by the end of January 2015
    ▪ A draft for biomarker committee review will be circulated
  o Drs. Armato and Siegelman are working on extracting a compliance checklist from the Profile for an “at-a-glance” reference
  o Once these steps are complete, the next phase will be the field test
    ▪ Drs. Gillies and Siegelman have volunteered to be initial testers of Profile implementation
  o Prior to implementing a field test, the Profile must be reviewed for the following:
    ▪ Is the Profile comprehensible in a real-world setting by a technologist?
    ▪ Are quantitative claims valid?
    ▪ Can a field test be done in parallel with Profile development?
      • Defining the “nature” of the Field Test is critical, e.g. what will input data look like, what will the output measurement/metric be, etc.
      • A virtual lab/platform with multiple readers and multiple labs was proposed as an option for consideration.
      • This would be related to an infrastructure for comparing algorithms
      • Prior to launching such a system, some studies need to be done to tease out variance
      • Breaking the claim into manageable components to validate separate portions and later bringing them back together for summation of the claim may be the only viable option
      • Short of a large clinical trial, consideration must be given to what can be done in the interim
        ▪ Repeatability parameters are still needed
        ▪ Ethical issues regarding patient management must be considered
        ▪ The Profile must be validated in a real-world setting
        ▪ Consideration to be given to piggy-backing a test of the Profile onto an existing clinical trial through partner organizations

Action items: Mr. Buckler to summarize future directions for discussion at the next Biomarker Committee meeting

Next Call: January 5th or January 12th – Next call for the CT Volumetry Biomarker Committee (?) – Co-Chairs to confirm.